ZA200207935B - A use of galantamine for the treatment of neuropsychiatric behaviour associated with Alzheimer's disease. - Google Patents
A use of galantamine for the treatment of neuropsychiatric behaviour associated with Alzheimer's disease. Download PDFInfo
- Publication number
- ZA200207935B ZA200207935B ZA200207935A ZA200207935A ZA200207935B ZA 200207935 B ZA200207935 B ZA 200207935B ZA 200207935 A ZA200207935 A ZA 200207935A ZA 200207935 A ZA200207935 A ZA 200207935A ZA 200207935 B ZA200207935 B ZA 200207935B
- Authority
- ZA
- South Africa
- Prior art keywords
- day
- galantamine
- dose
- dosage
- followed
- Prior art date
Links
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 title claims description 139
- 229960003980 galantamine Drugs 0.000 title claims description 69
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 title claims description 69
- 208000024827 Alzheimer disease Diseases 0.000 title claims description 22
- 239000003814 drug Substances 0.000 claims description 16
- 238000004448 titration Methods 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims 5
- 239000000902 placebo Substances 0.000 description 25
- 229940068196 placebo Drugs 0.000 description 25
- 230000008859 change Effects 0.000 description 24
- 238000012360 testing method Methods 0.000 description 16
- 230000006399 behavior Effects 0.000 description 15
- 229940079593 drug Drugs 0.000 description 12
- 230000002411 adverse Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 102100034112 Alkyldihydroxyacetonephosphate synthase, peroxisomal Human genes 0.000 description 8
- 101000799143 Homo sapiens Alkyldihydroxyacetonephosphate synthase, peroxisomal Proteins 0.000 description 8
- 238000000848 angular dependent Auger electron spectroscopy Methods 0.000 description 8
- 230000001149 cognitive effect Effects 0.000 description 8
- 238000012423 maintenance Methods 0.000 description 7
- 206010042772 syncope Diseases 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 102100039554 Galectin-8 Human genes 0.000 description 5
- 101001011019 Gallus gallus Gallinacin-10 Proteins 0.000 description 5
- 101000887168 Gallus gallus Gallinacin-8 Proteins 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 238000007492 two-way ANOVA Methods 0.000 description 5
- BLGKYYVFGMKTEZ-QVCIKPHISA-N D-galactosyl-N-hexadecanoylsphinganine Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)CCCCCCCCCCCCCCC)COC1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BLGKYYVFGMKTEZ-QVCIKPHISA-N 0.000 description 4
- SNPQGCDJHZAVOB-LUUMFRNDSA-N D-galactosyl-N-tetracosanoylsphinganine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)CCCCCCCCCCCCCCC)COC1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O SNPQGCDJHZAVOB-LUUMFRNDSA-N 0.000 description 4
- 229930013930 alkaloid Natural products 0.000 description 3
- 230000003542 behavioural effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 230000006866 deterioration Effects 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 206010000117 Abnormal behaviour Diseases 0.000 description 2
- 206010001497 Agitation Diseases 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 206010002942 Apathy Diseases 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 description 2
- 206010012239 Delusion Diseases 0.000 description 2
- 206010013142 Disinhibition Diseases 0.000 description 2
- 206010013954 Dysphoria Diseases 0.000 description 2
- 241001539473 Euphoria Species 0.000 description 2
- 206010015535 Euphoric mood Diseases 0.000 description 2
- 208000004547 Hallucinations Diseases 0.000 description 2
- 208000001456 Jet Lag Syndrome Diseases 0.000 description 2
- 206010026749 Mania Diseases 0.000 description 2
- 206010057852 Nicotine dependence Diseases 0.000 description 2
- 208000025569 Tobacco Use disease Diseases 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 230000016571 aggressive behavior Effects 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 201000007930 alcohol dependence Diseases 0.000 description 2
- 150000003797 alkaloid derivatives Chemical group 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 230000002917 arthritic effect Effects 0.000 description 2
- 239000000544 cholinesterase inhibitor Substances 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 231100000868 delusion Toxicity 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229940006388 galantamine 8 mg Drugs 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 description 2
- 230000007074 memory dysfunction Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- GXFZCDMWGMFGFL-KKXMJGKMSA-N (+)-Tubocurarine chloride hydrochloride Chemical compound [Cl-].[Cl-].C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CC[NH+]3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 GXFZCDMWGMFGFL-KKXMJGKMSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 102100033639 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 108010053652 Butyrylcholinesterase Proteins 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102100032404 Cholinesterase Human genes 0.000 description 1
- 229940122041 Cholinesterase inhibitor Drugs 0.000 description 1
- 241001111317 Chondrodendron tomentosum Species 0.000 description 1
- 238000000959 Cochran–Mantel–Haenszel (CMH) test Methods 0.000 description 1
- 239000008709 Curare Substances 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- 206010013486 Distractibility Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000001375 Facial Neuralgia Diseases 0.000 description 1
- 241000234271 Galanthus Species 0.000 description 1
- 241001502107 Galanthus alpinus Species 0.000 description 1
- 241000234283 Galanthus nivalis Species 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 241000234479 Narcissus Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
- 101100532451 Rattus norvegicus Slc22a17 gene Proteins 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000718 cholinopositive effect Effects 0.000 description 1
- 230000002060 circadian Effects 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000003931 cognitive performance Effects 0.000 description 1
- 208000012790 cranial neuralgia Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229960002024 galantamine hydrobromide Drugs 0.000 description 1
- QORVDGQLPPAFRS-XPSHAMGMSA-N galantamine hydrobromide Chemical compound Br.O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 QORVDGQLPPAFRS-XPSHAMGMSA-N 0.000 description 1
- 230000003370 grooming effect Effects 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- -1 pessaries Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000036314 physical performance Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000012313 reversal agent Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000006403 short-term memory Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19425900P | 2000-04-03 | 2000-04-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200207935B true ZA200207935B (en) | 2004-01-30 |
Family
ID=22716898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200207935A ZA200207935B (en) | 2000-04-03 | 2002-10-02 | A use of galantamine for the treatment of neuropsychiatric behaviour associated with Alzheimer's disease. |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1272192A2 (hu) |
| JP (1) | JP2003528913A (hu) |
| KR (1) | KR20020086911A (hu) |
| CN (1) | CN1430514A (hu) |
| AU (2) | AU6584401A (hu) |
| BG (1) | BG107093A (hu) |
| BR (1) | BR0109770A (hu) |
| CA (1) | CA2310926C (hu) |
| CZ (1) | CZ20023543A3 (hu) |
| EE (1) | EE200200554A (hu) |
| HR (1) | HRP20020778A2 (hu) |
| HU (1) | HUP0300566A3 (hu) |
| IL (1) | IL152061A0 (hu) |
| MX (1) | MXPA02009777A (hu) |
| NO (1) | NO20024746L (hu) |
| PL (1) | PL361272A1 (hu) |
| RU (1) | RU2002129298A (hu) |
| SK (1) | SK15422002A3 (hu) |
| WO (1) | WO2001074339A2 (hu) |
| ZA (1) | ZA200207935B (hu) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6617361B2 (en) * | 1999-11-05 | 2003-09-09 | Be Able, Llc | Behavior chemotherapy |
| BRPI0412919A (pt) | 2003-07-25 | 2006-09-26 | Hoffmann La Roche | combinação de antagonista de mglur2 e inibidor de ache para o tratamento de distúrbios neurológicos crÈnicos e/ou agudos |
| DE10338544B4 (de) * | 2003-08-19 | 2017-08-31 | Janssen Pharmaceutica N.V. | Buccale Formulierungen des Galanthamins und deren Anwendungen |
| MX2010010460A (es) | 2008-03-27 | 2010-12-15 | Chase Pharmaceuticals Corp | Uso y composicion para tratar la demencia. |
| WO2013160728A1 (en) | 2012-04-26 | 2013-10-31 | Alma Mater Studiorum - Universita' Di Bologna | Dual targeting compounds for the treatment of alzheimer's disease |
| BG66818B1 (bg) * | 2013-03-07 | 2019-01-31 | Berbee Beheer B. V. | Състав на екстракт от hippeastrum papilio за производство на лекарствени средства и хранителни добавки |
| EP3297632A4 (en) * | 2015-05-18 | 2019-01-16 | Synaptec Development LLC | GALANTAMINE ELIMINATION OF AMYLOIDSS |
| WO2023036105A1 (zh) * | 2021-09-09 | 2023-03-16 | 上海日馨医药科技股份有限公司 | 治疗神经退行性疾病的方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4663318A (en) * | 1986-01-15 | 1987-05-05 | Bonnie Davis | Method of treating Alzheimer's disease |
| DE19509663A1 (de) * | 1995-03-17 | 1996-09-19 | Lohmann Therapie Syst Lts | Verfahren zur Isolierung von Galanthamin |
| GB9600080D0 (en) * | 1996-01-04 | 1996-03-06 | Chiroscience Ltd | Resolution process |
| AU1738800A (en) | 1998-11-23 | 2000-06-13 | Bonnie Davis | Dosage formulations for acetylcholinesterase inhibitors |
| HUP0104778A3 (en) * | 1998-12-24 | 2004-05-28 | Janssen Pharmaceutica Nv | Controlled release galantamine composition |
| CA2310950C (en) * | 2000-04-03 | 2005-11-08 | Janssen Pharmaceutica N.V. | An efficacious dosage regiment of galantamine that reduces side effects |
| CA2310990A1 (en) * | 2000-04-03 | 2000-10-09 | Michael Pontecorvo | A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease |
-
2000
- 2000-06-27 CA CA002310926A patent/CA2310926C/en not_active Expired - Lifetime
-
2001
- 2001-03-28 CZ CZ20023543A patent/CZ20023543A3/cs unknown
- 2001-03-28 AU AU6584401A patent/AU6584401A/xx active Pending
- 2001-03-28 IL IL15206101A patent/IL152061A0/xx unknown
- 2001-03-28 HU HU0300566A patent/HUP0300566A3/hu unknown
- 2001-03-28 MX MXPA02009777A patent/MXPA02009777A/es unknown
- 2001-03-28 JP JP2001572084A patent/JP2003528913A/ja not_active Withdrawn
- 2001-03-28 WO PCT/EP2001/003553 patent/WO2001074339A2/en not_active Application Discontinuation
- 2001-03-28 BR BR0109770-9A patent/BR0109770A/pt not_active IP Right Cessation
- 2001-03-28 KR KR1020027011063A patent/KR20020086911A/ko not_active Application Discontinuation
- 2001-03-28 EE EEP200200554A patent/EE200200554A/xx unknown
- 2001-03-28 PL PL36127201A patent/PL361272A1/xx not_active Application Discontinuation
- 2001-03-28 EP EP01943200A patent/EP1272192A2/en not_active Withdrawn
- 2001-03-28 CN CN01807334A patent/CN1430514A/zh active Pending
- 2001-03-28 AU AU2001265844A patent/AU2001265844B2/en not_active Ceased
- 2001-03-28 SK SK1542-2002A patent/SK15422002A3/sk unknown
- 2001-03-28 RU RU2002129298/14A patent/RU2002129298A/ru not_active Application Discontinuation
-
2002
- 2002-09-12 BG BG107093A patent/BG107093A/bg unknown
- 2002-09-26 HR HR20020778A patent/HRP20020778A2/xx not_active Application Discontinuation
- 2002-10-02 ZA ZA200207935A patent/ZA200207935B/en unknown
- 2002-10-02 NO NO20024746A patent/NO20024746L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PL361272A1 (en) | 2004-10-04 |
| EP1272192A2 (en) | 2003-01-08 |
| BG107093A (bg) | 2003-06-30 |
| AU2001265844B2 (en) | 2005-04-14 |
| MXPA02009777A (es) | 2003-03-27 |
| HUP0300566A3 (en) | 2004-10-28 |
| AU6584401A (en) | 2001-10-15 |
| KR20020086911A (ko) | 2002-11-20 |
| BR0109770A (pt) | 2003-02-04 |
| NO20024746D0 (no) | 2002-10-02 |
| CZ20023543A3 (cs) | 2003-03-12 |
| CA2310926A1 (en) | 2000-10-04 |
| JP2003528913A (ja) | 2003-09-30 |
| EE200200554A (et) | 2004-04-15 |
| RU2002129298A (ru) | 2004-03-27 |
| HRP20020778A2 (en) | 2004-04-30 |
| IL152061A0 (en) | 2003-05-29 |
| NO20024746L (no) | 2002-11-28 |
| SK15422002A3 (sk) | 2003-04-01 |
| WO2001074339A2 (en) | 2001-10-11 |
| CN1430514A (zh) | 2003-07-16 |
| HUP0300566A2 (hu) | 2003-06-28 |
| CA2310926C (en) | 2002-10-15 |
| WO2001074339A3 (en) | 2002-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4097285B2 (ja) | 種々の頑固な疾患の治療のための医薬の製造に有用な組成物 | |
| AU621035B2 (en) | The administration of monoamine acridines in cholinergic neuronal deficit states | |
| Bentue-Ferrer et al. | Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologists | |
| EA012325B1 (ru) | Терапевтические составы для лечения болезней, связанных с наличием бета-амилоида | |
| Csernansky et al. | Double-blind comparison of alprazolam, diazepam, and placebo for the treatment of negative schizophrenic symptoms | |
| CA2310950C (en) | An efficacious dosage regiment of galantamine that reduces side effects | |
| JPH06507617A (ja) | 疲労症候群の治療 | |
| US20070264358A1 (en) | Methods and Compositions for Treating Mood Disorder | |
| KR20220012281A (ko) | 브루톤 티로신 키나제 저해제를 이용하여 만성 자발성 두드러기를 치료하는 방법 | |
| AU2001265844B2 (en) | A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease | |
| AU2001265844A1 (en) | A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease | |
| JPH0667842B2 (ja) | 基本的うつ病を軽減するためのうつ病治療剤 | |
| Campbell et al. | Evaluation of the drug treatment and persistence of onychomycosis | |
| US20060172993A1 (en) | Use of galantamine for the treatment of neuropsychiatric behaviour associated with Alzheimer's disease | |
| Stanaland | Treatment of patients with chronic idiopathic urticaria | |
| WO2020234780A1 (en) | Methods of treating asthma using a bruton's tyrosine kinase inhibitor | |
| JP2005306882A (ja) | 感情的不安定の治療のための医薬の製造に有用な組成物 | |
| RU2818678C2 (ru) | Способы лечения хронической спонтанной крапивницы с применением ингибитора тирозинкиназы брутона | |
| US20230364060A1 (en) | Methods and compositions for treating glucocorticoid excess | |
| Panas et al. | Belladonna alkaloids and phenobarbital use in the treatment of irritable bowel syndrome: a review | |
| CA2310990A1 (en) | A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease | |
| Nakamura et al. | Mianserin suppositories in the treatment of post‐operative delirium | |
| JP4372723B2 (ja) | 慢性疼痛の治療のための医薬の製造に有用な組成物 | |
| WO2021055576A1 (en) | Combination of modafinil and an ampakine for improving cognition | |
| de Haen | Annual Review of New Drugs |